Figure 1.

Magnitude, cross-reactivity, and durability of antibodies in sera from Pfizer vaccinees, with or without breakthrough BA.1/BA.2 infection

(A) Nab titers against D614G, Delta and Omicron BA.1, BA.2 and BA.5 were quantified in sera from triple vaccinated individuals (n = 24; median = 120 days after the third dose) (left panel) and after Omicron BA.1 or BA.2 breakthrough infection (n = 11; median = 80 days after infection). Data are the mean from two independent experiments. The horizontal dotted line indicates the limit of detection (ED₅₀ = 30). Black lines represent the median values. Two-sided Friedman test with Dunn’s test for multiple comparisons was performed between each viral strain at the different time points; ∗p < 0.05; ∗∗∗∗p < 0.0001.

(B) Temporal evolution of Nab titers (ED₅₀) against D614G (black), BA.1 (red) and BA.5 (yellow) in 27 vaccine recipients and 11 participants who had an Omicron BA.1 or BA.2 breakthrough infection. The Nab titers were calculated at the indicated months after the second dose (left panels), third dose (middle panels), or breakthrough infection (right panels). The bold dotted line included in some panels represents a simple linear regression of Nab waning. In the other panels, the shape of the curves did not allow this analysis. Data are the mean from two independent experiments. The horizontal dotted line indicates the limit of detection (ED₅₀ = 30).